TOKYO and CAMBRIDGE, Mass., September 25, 2023 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI? Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD).

Eisai Co., Ltd. (Headquarters: Tokyo) and Biogen Inc. (Headquarters: Cambridge, Massachusetts) announced the following joint statement regarding today’s recommendation by Japan’s First Committee on New Drugs of the Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labour and Welfare that the manufacturing and marketing authorization application for lecanemab (product names: Leqembi 200 mg for intravenous infusion and Leqembi 500 mg for intravenous infusion) should be approved.

Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest findings on its Alzheimer’s disease (AD) pipeline and research, including Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer’s disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI?), and the company’s investigational anti-MTBR** tau antibody, E2814, at the Alzheimer’s Association International Conference (AAIC). The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023. Eisai will present data and research in eight oral and 19 poster presentations at the meeting. Two of the AAIC oral presentations will be presented as posters at the Alzheimer’s Disease Imaging Consortium (AIC), which will be held at the same venue as AAIC on July 15.

· New research collaboration brings together world-leading institutions’ collective expertise in therapeutics, technology, health data, technology commercialisation and advanced analytics/data science in neurology.
· Two-year pilot provides a launch pad for translating scientific prototypes into practical solutions that demonstrate real-world impact.
· NEURii collaboration builds on Eisai’s extensive experience in delivering innovative treatments in neurology and supports ongoing contributions to the global digital health ecosystem.